• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Venture Capital Matters

#VentureCapital: VC meets social media

  • Pitch a Startup
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

NapaJen Pharma Closes $12.4 Million Series C Financing

January 9, 2019 By 3v.org Leave a Comment

NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, has announced the closing of a $12.4 million Series C financing deal. The financing was led by the existing investor, INCJ, Ltd., and included participation by existing investor Mitsui & Co. Global Investment and newly participating P&D Directions Inc.

The funding will be used to complete the Phase 1 clinical development of NJA-730 started in the autumn of 2018 in Australia and prepare for further development. NJA-730 is a novel immunosuppressive therapeutic agent that combines an anti-CD40 small interfering RNA (siRNA) with the company’s beta-glucan delivery technology. The primary objective of the study is to evaluate the safety and tolerability of NJA-730 administered intravenously. Key secondary objectives will include an assessment of the pharmacokinetic profile of the compound. Investigators will also evaluate the impact of NJA-730 on CD40 gene suppression.

NapaJen’s novel, proprietary delivery vehicle is built upon schizophyllan, a beta-glucan that specifically binds to Dectin-1, a cell surface receptor expressed on antigen presenting immune cells, namely dendritic cells and macrophages. By complexing oligonucleotides with schizophyllan, NapaJen’s delivery platform uniquely enables the efficient and selective delivery of oligonucleotides to cells playing key roles in regulating immune responses. The outcome of Phase 1 clinical trials of NJA-730 is expected to lend evidence of its efficiency and advance new modality of oligonucleotide-based therapeutics.

About NapaJen
NapaJen Pharma, Inc. is a clinical-stage, biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents. Founded in 2004 as a California corporation, NapaJen has developed a proprietary platform technology in which oligonucleotide compounds are stably and selectively delivered to immune cells. Leveraging the versatility of the platform technology, NapaJen aims to create new oligonucleotide therapeutics in the area of immune-related conditions, such as autoimmune diseases, cancer, transplantation and vaccine, through collaborative work with industry and academia.

SOURCE NapaJen Pharma, Inc.
http://www.napajen.com

Related

Filed Under: PR

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • FreshCut Secures $15M Funding to Accelerate Transformation of Web3 Gaming Content Ecosystem
  • Thought Machine Raises $160m in Series D Funding Round – Doubling Valuation to $2.7bn and Accelerating Plans to Bring World’s Banks Onto Cloud Technology
  • Foundational Skills Checklist
  • LucidLink Raises $20 Million in Series B to Solve Remote Collaboration Challenges for Global Creative Teams
  • Storyblok Raises $47M Series B Led by Mubadala Capital and HV Capital to Make Headless Content Management the New Standard
  • A bridge between Web2 and Web3
  • Fresh Technology Inc. Closes $7 Million Series A to Drive Innovation in Modern Restaurant Kitchens
  • SoftBank will be cutting its startup investments by 50-75% through March 2023
  • Paddle, which provides a billing backend for SaaS companies, raises a $200M Series D
  • RGo Robotics Exits Stealth Mode with $20M in Funding & Major Customer Wins

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Venture Capital

Copyright © 2018 3V.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT